Obesity worsens disability in multiple sclerosis

Obesity is an aggravating factor in relapsing-remitting multiple sclerosis, the most common form of the disease. A recent study by the Unit of Neurology and Neurorehabilitation of the I.R.C.C.S. Neuromed in Pozzilli (Italy) confirms that lipid metabolism can have a role in determining the severity of multiple sclerosis.

Published in the Multiple Sclerosis Journal, the research, involving 140 patients, showed that at the time of diagnosis obese patients have a greater risk of presenting higher EDSS (Expanded Disability Status Scale) score, the tool commonly used to assess the severity of multiple sclerosis. Neuromed researchers have also investigated, from a biochemical point of view, the relationship between multiple sclerosis and excessive body weight, analyzing the levels of inflammation in the central nervous system and the lipids concentrations in the blood (cholesterol and triglycerides).

Multiple sclerosis is an inflammatory process, and the authors of the study have focused their investigation on some molecules involved in inflammation. Analysis of cerebrospinal fluid (collected with lumbar puncture) showed in obese patients higher levels of interleukin-6 (IL-6) and leptin, two molecules well known as promoters of the inflammatory process. In contrast, interleukin-13 (IL-13), with anti-inflammatory action, was reduced. Regarding lipid profile, higher levels of triglycerides and a higher ratio of total to HDL cholesterol have been correlated to higher IL-6 levels.

“This study,” says Mario Stampanoni Bassi, Neurologist at Neuromed, “confirms that obesity is associated with greater symptomatic severity of relapsing-remitting multiple sclerosis. In particular, the analysis of cerebrospinal fluid has highlighted the role of leptin produced by fat cells. Previous studies have shown that leptin is directly involved in the complex relationship between metabolism and inflammation. Our results therefore suggest that excessive body weight, or altered lipid profile, are associated to increased central inflammation causing a worse clinical expression of the disease .”

Source: Read Full Article

Related posts:
  1. New drug candidates reverse drug resistance in multiple myeloma in preclinical models
  2. New clues to the origin and progression of multiple sclerosis
  3. The Lypla1 gene impacts obesity in a sex-specific manner
  4. The cycle of garbage in nature: where in the body plastic?
  5. Transplanting gut bacteria alters depression-related behavior, brain inflammation in animals